Class action filed against Zoetis over alleged misleading statements on product growth and market share.

A class action lawsuit has been filed against Zoetis Inc. and certain officers, alleging they made false statements about the growth and market share of key products in the Companion Animal segment. The complaint claims Zoetis failed to disclose weakening veterinarian adoption of Librela due to FDA safety warnings, loss of market share for Simparica Trio to cheaper competitors, and declining sales of dermatology products Apoquel and Cytopoint. Investors who bought Zoetis securities between January 14, 2025, and May 6, 2026, are encouraged to join the lawsuit, with a lead plaintiff deadline of July 27, 2026. The law firm Bronstein, Gewirtz & Grossman, LLC represents investors on a contingency basis, seeking to recover damages for alleged securities fraud.